Home/Apriori Bio/Harry Kleanthous, PhD

HK

Harry Kleanthous, PhD

Chief Scientific Officer

Therapeutic Areas

Infectious Disease

Apriori Bio Pipeline

Drug	Indication	Phase
Not Disclosed	Respiratory Viral Threats (e.g., Influenza, Pandemic Coronaviruses)	Pre-clinical

Leadership Team at Apriori Bio

Craig Williams, MBA

Chief Executive Officer

Lovisa Afzelius, PhD, MBA

Board Chair, Founding CEO

Daniel Acker, PhD

Co-Founder and Chief Innovation Officer

Seth Berkley, MD

Executive Vice Chairman

View full Apriori Bio profile